Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma:effect on mucosal inflammation and in vitro sensitivity to glucocorticoidsof mitogen-induced T-cell proliferation
B. Vrugt et al., Low-dose methotrexate treatment in severe glucocorticoid-dependent asthma:effect on mucosal inflammation and in vitro sensitivity to glucocorticoidsof mitogen-induced T-cell proliferation, EUR RESP J, 15(3), 2000, pp. 478-485
The authors have investigated whether the steroid-sparing effect of methotr
exate (MTX) in severe orally glucocorticoid-insensitive asthmatics may be a
ccounted for by the ability of this drug to increase the T-cell responsiven
ess sensitivity to dexamethasone in vitro. In addition the authors have inv
estigated whether low-dose MTX treatment is associated with anti-inflammato
ry effects in peripheral blood and the bronchial mucosa.
In eight patients with severe atopic asthma, using greater than or equal to
15 mg.day(-1) prednisolone, the inhibitory effect of dexamethasone on mito
gen stimulated peripheral blood mononuclear cells (PBMC) in vitro was teste
d before and after 8 weeks of uncontrolled treatment with MTX. Endobronchia
l biopsies were taken before and after MTX therapy in seven subsequent pati
ents, and analysed using immunohistochemistry. In eight patients, serum was
drawn for measuring levels of free interleukin (IL)-8.
The in vitro sensitivity of PBMC to dexamethasone (at 1.6X10(-9) and 3.2X10
(-10) mol.L-1) was significantly lower in the asthmatics before treatment w
hen compared with the control subjects (p=0.03 and =0.001) but increased si
gnificantly after MTX treatment (p=0.04 and =0.02) to normal responsiveness
. This was not associated with a decrease in peripheral blood T-cell number
s or activation. Except for a significant increase in the numbers of CD3+ (
p=0.04), no significant numerical changes in activated T-cells, eosinophils
, or mast cells were found (p>0.05). However, MTX treatment was associated
with a significant fall in serum levels of free IL-8 (p=0.03).
It is hypothesized that the steroid-sparing effect of methotrexate originat
es from increased sensitivity of lymphocytes to the inhibitory effects of g
lucocorticoids. The absence of an inhibitory effect on inflammatory cells i
n blood and mucosa suggests that this effect is achieved by modulating cell
function rather than cell number.